Vaxine was incorporated in 2002 as an Australian biotechnology company focussing on development of innovative vaccine technologies.
Vaxine was the first company in the world during the 2009 pandemic to bring a swine flu vaccine into human trials. In collaboration with the US Army, it is making rapid progress in development of a non-living Ebola vaccine.
Vaxine has won more than $25 million in competitive research contracts from the US government's National Institutes of Health over the last 10 years.
Most recently, Vaxine received major global publicity for its success with its US partner for the development of a vaccine against Alzheimer's disease.